Pazopanib clinical trials
Also written Votrient, GW786034B and GW786034.
How each study uses pazopanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pazopanib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Oct 2009 · VOTRIENT · NDA 022465 (FDA, Drugs@FDA)
- European Union
- 14 Jun 2010 · Votrient · EMEA/H/C/001141 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
211 studies that test it; most in 2010 (36)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 12 |
| 2007 | 12 |
| 2008 | 14 |
| 2009 | 12 |
| 2010 | 36 |
| 2011 | 32 |
| 2012 | 27 |
| 2013 | 12 |
| 2014 | 7 |
| 2015 | 18 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 3 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 55 · Other 157
GlaxoSmithKline (42) · National Cancer Institute (NCI) (24) · Novartis Pharmaceuticals (10) · M.D. Anderson Cancer Center (9) · Samsung Medical Center (8) · Washington University School of Medicine (4) · Northwestern University (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3)
Often tested with
Tested in the same studies.
Everolimus (9) · Paclitaxel (9) · Gemcitabine (8) · Sunitinib (7) · Temsirolimus (5) · Lapatinib (5) · Doxorubicin (4) · Topotecan (4)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Pazopanib is the comparator. A study of two new drugs counts under both.
- 1Olaparib · National Cancer Institute (NCI)
- 1Temozolomide · National Cancer Institute (NCI)
- 1Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 · Intensity Therapeutics, Inc. · next primary completion Dec 2027
- 1Nivolumab · Centre Leon Berard
- 1Ipilimumab · Centre Leon Berard
Reaching primary completion within a year · 3
Studies that test pazopanib.
- Dec 2026Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaPhase 2 · Yonsei University
- Feb 2027Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma MultiformePhase 1/2 · Centre Antoine Lacassagne
- Feb 2027Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerPhase 1/2 · Roswell Park Cancer Institute
Studies
Open first, then newest update. How each study uses pazopanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 212
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as PazopanibHow we know
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingPhase 1M.D. Anderson Cancer CenterNCT07444619Written as PazopanibHow we know
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingPhase 1/2St. Jude Children's Research HospitalNCT06239272Written as PazopanibHow we know
- Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaRecruitingPhase 2Yonsei UniversityNCT05679921Written as pembrolizumab, pazopanibHow we know
- Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)RecruitingPhase 1/2Tianjin Medical University Second HospitalNCT06895733Written as Pazopanib Oral TabletHow we know
- Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or AdolescentsRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT06816771Written as pazopanibHow we know
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingPhase 4University Medical Center GroningenNCT05949424Written as PazopanibHow we know
- Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic TelangiectasiaNot yet recruitingPhase 1/2Cure HHTNCT03850730Written as PazopanibHow we know
- Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid TumorsNot yet recruitingPhase 1/2Samsung Medical CenterNCT03628131Written as PazopanibHow we know
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01575548Written as Pazopanib HydrochlorideHow we know
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01552356Written as Pazopanib HydrochlorideHow we know
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01841736Written as Pazopanib HydrochlorideHow we know
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerActive, not recruitingPhase 1/2Roswell Park Cancer InstituteNCT01684397Written as Pazopanib HydrochlorideHow we know
- Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)CompletedPhase 2/3Cure HHTNCT03850964Written as PazopanibHow we know
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01217931Written as PazopanibHow we know
- Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid CarcinomaCompletedPhase 2Centre Leon BerardNCT01813136Written as Continuous pazopanib (Arm A)How we know
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedPhase 2/3National Cancer Institute (NCI)NCT02180867Written as PazopanibHow we know
- Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingPhase 1/2Centre Antoine LacassagneNCT02331498Written as PazopanibHow we know
- Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG CriteriaTerminatedPhase 1Institut Claudius RegaudNCT01642017Written as PazopanibHow we know
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaCompletedPhase 4Institut Claudius RegaudNCT02555748Written as PazopanibHow we know
See all 212 studies that test pazopanib →
Given beside what is tested · 24 — pazopanib is usual care or a partner of the new treatment
- A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaRecruitingPhase 2Imbioray (Hangzhou) Biomedicine Co., Ltd.NCT07087158Written as PazopanibHow we know
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Pazopanib (800 mg QD)How we know
- A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)RecruitingPhase 3Xynomic Pharmaceuticals, Inc.NCT03592472Written as PazopanibHow we know
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT02009449Written as PazopanibHow we know
- HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue SarcomasActive, not recruitingPhase 1/2Centre Leon BerardNCT05180695Written as PazopanibHow we know
- Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerCompletedPhase 1/2European Organisation for Research and Treatment of Cancer - EORTCNCT01402271Written as pazopanib hydrochlorideHow we know
- Pazopanib and ARQ 197 for Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01468922Written as PazopanibHow we know
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT01664182Written as Pazopanib HydrochlorideHow we know
- Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by SurgeryTerminatedPhase 2Academic and Community Cancer Research UnitedNCT03334409Written as Pazopanib HydrochlorideHow we know
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedPhase 1Bristol-Myers SquibbNCT01472081Written as PazopanibHow we know
- PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian CancerTerminatedPhase 1/2The Christie NHS Foundation TrustNCT02055690Written as PazopanibHow we know
- Pazopanib Tolerability When Given With FoodCompletedPhase 1Radboud University Medical CenterNCT02138526Written as pazopanibHow we know
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue SarcomaCompletedPhase 1/2Tracon Pharmaceuticals Inc.NCT01975519Written as TRC105 and PazopanibHow we know
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced AngiosarcomaCompletedPhase 3Tracon Pharmaceuticals Inc.NCT02979899Written as VotrientHow we know
- Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone MetsCompletedPhase 1Dana-Farber Cancer InstituteNCT02406521Written as PazopanibHow we know
- Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney CancerTerminatedPhase 1Virginia Commonwealth UniversityNCT02795819Written as PazopanibHow we know
- Phase I Study of MLN8237 and Pazopanib in Patients With Solid TumorsCompletedPhase 1University of Illinois at ChicagoNCT01639911Written as PazopanibHow we know
- Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and CholangiocarcinomaCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01438554Written as PazopanibHow we know
- A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT00619424Written as pazopanibHow we know
- Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)CompletedPhase 1GlaxoSmithKlineNCT00387387Written as PazopanibHow we know
Showing 20 of 24.
As the comparator · 8 — what is tested is compared with pazopanib
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)RecruitingPhase 3Intensity Therapeutics, Inc.NCT06263231Written as PazopanibHow we know
- Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeRecruitingPhase 3Centre Leon BerardNCT04741438Written as Pazopanib Oral Tablet [Votrient]How we know
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped WorkingActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT05432791Written as PazopanibHow we know
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedPhase 3Incyte CorporationNCT03260894Written as PazopanibHow we know
- Phase 3 Study to Treat Patients With Soft Tissue SarcomasCompletedPhase 3ImmunityBio, Inc.NCT02049905Written as Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)How we know
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease ControlTerminatedPhase 2AIO-Studien-gGmbHNCT02959554Written as PazopanibHow we know
- Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal TumorsStatus unknownNot applicableUniversity Hospital, GrenobleNCT03571438Written as PazopanibHow we know
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical CancerCompletedPhase 2GlaxoSmithKlineNCT00430781Written as pazopanib (GW786034)How we know
Codes
What other systems call pazopanib · ClinicalTrials.gg INT005030
- MeSH (NLM) C516667pazopanibConfirmed NLM, Wikidata
- UNII (FDA) 7RN5DR86CKPAZOPANIBConfirmed FDA, NLM, Wikidata
- RxNorm 714438Confirmed FDA, Wikidata
- Wikidata Q7157043pazopanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74547PazopanibOne source FDA
- DrugBank DB06589One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C516667 | pazopanib | Confirmed NLM, Wikidata |
| UNII (FDA) | 7RN5DR86CK | PAZOPANIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 714438 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7157043 | pazopanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74547 | Pazopanib | One source FDA |
| DrugBank | DB06589 | — | One source Wikidata |
Also registered as pazopanib hydrochloride (UNII 33Y9ANM545 · RxNorm 732187).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.